702 related articles for article (PubMed ID: 18997742)
21. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
22. Strong medicine.
Wadman M
Nat Med; 2005 May; 11(5):465-6. PubMed ID: 15875044
[No Abstract] [Full Text] [Related]
23. The Kennedy version of the Drug Regulation Reform Act.
Greenberg RB
Am J Hosp Pharm; 1979 Sep; 36(9):1230-4. PubMed ID: 386790
[TBL] [Abstract][Full Text] [Related]
24. Informed consent elements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2011 Jan; 76(2):256-70. PubMed ID: 21261126
[TBL] [Abstract][Full Text] [Related]
25. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
26. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
27. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
28. New National Institutes of Health website helps locate clinical trials.
SoRelle R
Circulation; 2000 Mar; 101(10):E9021. PubMed ID: 10715281
[No Abstract] [Full Text] [Related]
29. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
Poser S
Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
[No Abstract] [Full Text] [Related]
30. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
32. A needed technical fix?
Robertson WO
Vet Hum Toxicol; 2000 Apr; 42(2):118-9. PubMed ID: 10750184
[No Abstract] [Full Text] [Related]
33. Paediatric clinical trials: redressing the imbalance.
Schreiner MS
Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
[No Abstract] [Full Text] [Related]
34. Transparency for clinical trials--the TEST Act.
Drazen JM
N Engl J Med; 2012 Aug; 367(9):863-4. PubMed ID: 22873430
[No Abstract] [Full Text] [Related]
35. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
36. Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
Reichertz PS
Food Drug Law J; 1996; 51(3):355-65. PubMed ID: 11797712
[No Abstract] [Full Text] [Related]
37. US launches new clinical trials database.
Charatan F
BMJ; 2000 Mar; 320(7236):668. PubMed ID: 10710566
[No Abstract] [Full Text] [Related]
38. Surfing for studies. Clinical trials on the Internet.
Dresser R
Hastings Cent Rep; 1999; 29(6):26-7. PubMed ID: 10641241
[No Abstract] [Full Text] [Related]
39. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
Ehrenpreis ED; Ciociola AA; Kulkarni PM;
Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
[No Abstract] [Full Text] [Related]
40. FDA gene rules impractical.
Morrison C
Nat Biotechnol; 2001 Jan; 19(1):5. PubMed ID: 11135515
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
